Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Daniel S, Richards"'
Autor:
Katarina Kadlecikova, John R. Rizzo, Mo Jia, Peter G. Houghton, Conchita Fernandez Garcia, Kevin P. Cole, Jeffery Richardson, Jared L. Piper, Junliang Hao, Amy C. DeBaillie, Peng Liu, Daniel S. Richards, Ping Huang
Publikováno v:
Organic Process Research & Development. 24:2549-2564
The evolution from early medicinal chemistry to large-scale production of the chemical synthesis of Lilly D1 positive allosteric modulator mevidalen (LY3154207) and its hydroxybenzoate cocrystal is...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20e6fb959778af8ddfb00a678ada3a5c
https://doi.org/10.1021/acs.oprd.0c00229
https://doi.org/10.1021/acs.oprd.0c00229
Autor:
Robert F. Bruns, Qi Chen, Paloma Vidal, John Mehnert Schaus, Charles R. Yang, Stephen N. Mitchell, Steven Marc Massey, Nuria Diaz, Xushan Wang, David Andrew Coates, Rebecca A. Wright, Beverly A. Heinz, Kevin Matthew Gardinier, Greg Stephenson, James P. Beck, Rajni M. Bhardwaj, Julie F. Falcone, Bruce A. Dressman, Deanna L Maren, Anette M. Johansson, David Michael Remick, Jeff W. Cramer, Cohen Michael Philip, Brian Morgan Watson, Jeffery Richardson, Kjell Svensson, Xin Zhou, Erik James Hembre, Serge Louis Boulet, Reinhard Matthew Robert, Daniel S. Richards, Junliang Hao, David M. Bender, Guy Carter, Christopher David Beadle, Brian G. Getman, Wolfangel Craig Daniel, Diseroad Benjamin Alan, Jason K. Myers, Joseph H. Krushinski, David Edward Tupper
Publikováno v:
Journal of Medicinal Chemistry. 62:8711-8732
Clinical development of catechol-based orthosteric agonists of the dopamine D1 receptor has thus far been unsuccessful due to multiple challenges. To address these issues, we identified LY3154207 (...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a353395d3c6f7ca6dfa78c95a347dd4
https://doi.org/10.1021/acs.jmedchem.9b01234
https://doi.org/10.1021/acs.jmedchem.9b01234
Autor:
Junliang, Hao, James P, Beck, John M, Schaus, Joseph H, Krushinski, Qi, Chen, Christopher D, Beadle, Paloma, Vidal, Matthew R, Reinhard, Bruce A, Dressman, Steven M, Massey, Serge L, Boulet, Michael P, Cohen, Brian M, Watson, David, Tupper, Kevin M, Gardinier, Jason, Myers, Anette M, Johansson, Jeffery, Richardson, Daniel S, Richards, Erik J, Hembre, David M, Remick, David A, Coates, Rajni M, Bhardwaj, Benjamin A, Diseroad, David, Bender, Greg, Stephenson, Craig D, Wolfangel, Nuria, Diaz, Brian G, Getman, Xu-Shan, Wang, Beverly A, Heinz, Jeff W, Cramer, Xin, Zhou, Deanna L, Maren, Julie F, Falcone, Rebecca A, Wright, Stephen N, Mitchell, Guy, Carter, Charles R, Yang, Robert F, Bruns, Kjell A, Svensson
Publikováno v:
Journal of medicinal chemistry. 62(19)
Clinical development of catechol-based orthosteric agonists of the dopamine D1 receptor has thus far been unsuccessful due to multiple challenges. To address these issues, we identified LY3154207 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::38771cd6f379be26a1a0dc76826df19b
https://pubmed.ncbi.nlm.nih.gov/31532644
https://pubmed.ncbi.nlm.nih.gov/31532644